(Oslo, 14th of April 2026) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the Board of Medistim ASA has approved the Financial Statements for 2025. The Financial Statements are without changes from the preliminary Financial Statements published on the 27th of February 2026. The annual report for 2025 is now available.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Kari E. Krogstad
MEDI: Medistim sponsors RCT trial comparing the use of TTFM with non-use in CABG
(Oslo, February 24, 2026) - Medistim ASA (OSE: MEDI), a leading niche provider of ultrasound technology headquartered in Oslo, Norway, today announced the commencement of SMARTFLOW, a randomized clinical trial (RCT) comparing the use of Transit Time Flow Measurement (TTFM) with non-use in coronary artery bypass graft (CABG) surgery. The SMARTFLOW trial is an expertise-based, multicenter, single-blind, randomized study enrolling 1,242 patients across approximately 20 centers worldwide.
Medistim: MEDI: Notice of Annual General Meeting in Medistim ASA
(Oslo, 10th of April 2025) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarters in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces the Annual General Meeting for the company. The Annual General Meeting will take place on the 8th of May 2025 at 10.00 and is held at Medistim's offices at Økernveien 94 in Oslo.
MEDI: Board approval of the 2024 Financial statements for Medistim ASA
(Oslo, 8th of April 2025) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the Board of Medistim ASA has approved the Financial Statements for 2024. The Financial Statements are without changes from the preliminary Financial Statements published on the 28th of February 2025. The annual report for 2024 is now available.
Medistim: MEDI: Medistim strengthens its Commercial Operations
(Oslo, 31 January 2025) Medistim ASA (OSE: MEDI) is a niche market leader within ultrasound technology with headquarters in Oslo, Norway. Medistim develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery. Today, the company announces the strengthening of its commercial operations with the appointment of Mr. Mike Karim as Chief Commercial Officer (CCO), reporting to the President and CEO.
Medistim launches clinical study on TTFM and HFUS in Vascular surgery
Real-time 08:13:21 2024-11-14 am EST 5-day change 1st Jan Change 135.50 NOK -3.21% -2.52% -36.68% Oct. 28 DNB lowers Medistim to 'keep' (buy), target price 172 Norwegian kroner - BN FW Oct. 24 Medistim ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI November 14, 2024 at 08:15 am EST (Oslo, 14 November 2024) Medistim ASA (OSE: MEDI) is a niche market leader within ultrasound technology with headquarters in Oslo, Norway.
Medistim: MEDI: Medistim Announces Launch of MiraQ INTUI Software P...
Oslo, 11 November 2024) Medistim ASA (OSE: MEDI) is a niche market leader within ultrasound technology with headquarters in Oslo, Norway. Medistim develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery. The company is pleased to announce the successful completion of its Early Access program for the new MiraQTM INTUI software platform. The official product launch is set for December 13 at the International Coronary Congress (ICC) in London.
Medistim Announces Partnership with Groundbreaking Cardiac Surgery Trial Exclusively Dedicated to Women
(Oslo, June 5, 2023) Medistim ASA (OSE: MEDI), a global niche market leader in ultrasound technology for medical use in Cardiac, Vascular and Transplant surgery, is pleased to announce its partnership with ROMA-Women, a groundbreaking cardiac surgery trial that is specifically focused on women. Historically, cardiovascular research and treatment protocols have primarily focused on men, leaving women underrepresented in clinical studies and potentially receiving suboptimal care.
Notification of trade
President and CEO in Medistim ASA, Kari E. Krogstad , has sold 37,719 shares to Medistim's largest shareholder Aeternum Capital AS, at 265.00 NOK per share. The sale is related to the CEO's private economy and need to free up liquidity. After the sale, Kari E. Krogstad holds a total of 38,083 shares in Medistim and Aeternum Capital AS holds 1,900,219 Medistim shares, which represent 10.16 % of the total shares in Medistim.
Notice of Annual General Meeting in Medistim ASA
(Oslo, 3rd of April 2023) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarters in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces the Annual General Meeting for the company. The Annual General Meeting will take place on the 24th of April 2023 at 10.00 and is held at Medistim's offices at Økernveien 94 in Oslo.
Medistim is opening a direct sales office in China
(Oslo, April 3, 2023) Medistim ASA (OSE: MEDI) is a niche market leader in ultrasound technology, headquartered in Oslo, Norway. The company develops and commercializes medical equipment for use in Cardiac, Vascular, and Transplant surgery. Today, Medistim announce that they are expanding their market coverage in China by establishing a direct sales office, opening today.
Annual report for 2022 for Medistim ASA
(Oslo, 30th of March 2023) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the Annual Report for 2022 is approved and available. About Medistim: Medistim was established in 1984, and has a track record of profitable growth over the past >15 years.
Medistim Expands Market Coverage in Canada by Going Direct
(Oslo, March 20, 2023) Medistim ASA (OSE: MEDI) is a niche market leader in ultrasound technology with headquarters in Oslo, Norway. The company develops and commercializes medical equipment for use in cardiac, vascular, and transplant surgery. Today, Medistim announce that they will expand their market coverage in Canada by establishing a direct sales operation.
Medistim to host a Capital Markets Day on Tuesday 21st of March 2023
(Oslo, 23rd February 2023) Medistim ASA (OSE: MEDI) is a niche market leader within ultrasound technology with headquarters in Oslo, Norway. Medistim develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery. Today, the company announces that they will hold a Capital Markets Day at Grand Hotel, Oslo, on March 21st from 9 am to 11 am. Breakfast will be served from 8:30.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Kari E.
Contact Kari E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack